Menu
Advanced
Structure search
List search
EN
CN
ES
FR
JP
KR
Wish Lists
Cart
Sign in
Sign in
Contact us
Catalog
of Screening Compounds
Screening Libraries
Building Blocks
Advanced
Structure search
List search
Homepage
>
Company
>
Media
>
Pharma News
>
2018
Pharma News, 2018
Celgene Corporation Announces Departure of President and Chief Operating Officer Scott A. Smith
SUMMIT, N.
High-flying biotech Loxo tempers bullish view for cancer drug
STAMFORD, Connecticut (Reuters) - In record time, Loxo Oncology (LOXO.
Pfizer signs deal with Allogene to develop cancer cell therapy
(Reuters) - Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to further devel...
Harvard Researchers Look to the Fetus for Better Wound Healing
In-utero healing has provided a new pathway for better wound recovery.
Senators launch probe into why price of cancer drug increased 1400 percent
Three U.
A Dangerous Antibiotic-Resistant Gene Has Spread The World. We Now Know Where It Started
The mcr-1 gene, which helps bacteria resist colistin – one of the few remaining antibiotic drugs of last resort that still work – has now reached hospitals all across the world.
New drug attacks cancer-causing genes
Two recent papers attack two cancer-related problems using the same drug.
Genentech offers HEMLIBRA update
Genentech.
New Large-Scale Trial Results Show Stiolto® Respimat® Prevents COPD Exacerbations Better Than Spiriva® Respimat®
RIDGEFIELD, Conn.
Bluebird, Celgene to share U.S. costs, profits on lead cancer CAR-T
Bluebird bio has pulled the trigger on an option to co-develop and co-promote the anti-BCMA CAR-T treatment, bb2121, with Celgene in the U.
FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
THOUSAND OAKS, Calif.
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint
Pfizer Inc.
50
51
52
53
54
55
56
57
58
0
item
s
in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Preplated libraries
Inhibitors and Approved Drugs
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Hit Follow up Support
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
Trends in discovery compounds
